CYP2C9 基因多态性与磺酰脲类降糖药药代动力学药效学相关性的研究进展

摘要/Abstract

摘要： 磺酰脲类是目前临床上广泛使用的口服降糖药, 在人体内通过具有基因多态性的CYP2C9 酶代谢。不同基因型CYP2C9 酶代谢活性的差异, 是造成患者所需磺酰脲类口服降糖药剂量个体差异大的因素之一。本文综合国内外最新报道, 阐述了CYP2C9 基因多态性与磺酰脲类口服降糖药药动学、药效学相关性的研究进展, 为制定磺酰脲类降糖药的个体化用药方案提供参考。

关键词: 细胞色素P450 2C9, 基因多态性, 磺酰脲类, 药动学, 药效学

Abstract: Sulphonylureas are the initial and most commonly used therapy for type 2 diabetes mellitus.Sulphonylureas are metabolized by CYP2C9, and the CYP2C9 gene has several mutant alleles leading to genetic polymorphisms in humans.The variation of metabolism abilities of different CYP2C9 genotype is one of the reasons why the type 2 diabetes mellitus patients need different doses of sulphonylureas.To offer a guidance for individualizing administration of sulphonylureas, we specify the relationship between genetic polymorphisms in CYP2C9 and the pharmacokinetics and pharmacodynamics of sulphonylureas.

Key words: CYP2C9, genetic polymorphisms, sulphonylureas, pharmacokinetics, pharmacodynamics

中图分类号:

R966

黄作君, 黎月玲, 黄民. CYP2C9 基因多态性与磺酰脲类降糖药药代动力学药效学相关性的研究进展[J]. 中国临床药理学与治疗学, 2007, 12(2): 219-223.

HUANG Zuo-jun, LI Yue-ling, HUANG Min. Recent advance in association between genetic polymorphisms in CYP2C9 and pharmacokinetics and pharmacodynamics of sulphonylureas[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 219-223.

参考文献

[1] 胡绍文. 口服降糖药的临床应用[A]. 见:胡绍文, 郭瑞林,童光焕, 主编.实用糖尿病学[M]. 第2 版.北京:人民军医出版社, 2003:160-166.
[2] Inzucchi SE.Oral antihyperglycemic therapy for type 2 diabetes: scientific review[J]. Jama, 2002;287:360-372.
[3] Christopher DM, Lawrence SP, David CZ, et al. Hypoglycemia in patients with type 2 diabetes mellitus[J]. Arch Intern Med,2001;161:1653-1659.
[4] Julia K, Jǜrgen B.Clinical consequences of cytochrome P450 2C9 polymorphisms[J]. Clin Pharmacol Ther, 2005;77:1-16.
[5] Bae JW, Kim HK, Kim JH, et al. Allele and genotype frequencies of CYP2C9 in a Korean population[J]. Br J Clin Pharmacol, 2005;60:418-422.
[6] Nakai K, Habano W, Nakai K, et al. Ethnic differences in CYP2C9*2 (Arg144Cys)and CYP2C9*3 (Ile359Leu)genotypes in Japanese and Israeli populations[J]. Life Sci, 2005; 78:107-111.
[7] 李健, 文思远, 王睿, 等.细胞色素P450 CYP2C9 基因多态性对甲苯磺丁脲代谢动力学的影响[J]. 药学学报,2005;40:695-699.
[8] Lee SS, Kim KM, Thi-Le H, et al. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population[J]. Ther Drug Monit, 2005;27:208-210.
[9] Adithan C, Gerard N, Vasu S, et al. Allele and genotype frequency of CYP2C9 in Tamilnadu population[J]. Eur J Clin Pharmacol, 2003;59:707-709.
[10] Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population[J]. Eur J Clin Pharmacol, 2004;60:337-342.
[11] Allabi AC, Gala JL, Desager JP, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations[J]. Br J Clin Pharmacol, 2003;56:653-657.
[12] Bozina N, Granic P, Lalic Z, et al. Genetic polymorphisms of cytochromes P450:CYP2C9, CYP2C19, and CYP2D6 in Croatian population[J]. CroatMed J, 2003;44:425-428.
[13] BurianM, Grosch S, Tegeder I, et al. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population[J]. Br J Clin Pharmacol, 2002;54:518-521.
[14] Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping:frequencies of mutant alleles in a Swedish population[J]. Biochem Biophys Res Commun, 1999;27:628-631.
[15] Hamdy SI, Hiratsuka M, Narahara K, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD)in the Egyptian population[J]. Br J Clin Pharmacol,2002;53:596-603.
[16] Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5)expressed among African Americans[J]. Mol Pharmacol, 2001;60:382-387.
[17] Joyce B, Lucia F, Sherry C, et al. Discovery of new potentially defective alleles of human CYP2C9[J]. Pharmacogenetics,2004;14:527-537.
[18] Guo Y, Zhang Y, Wang Y, et al. Role of CYP2C9 and its variants (CYP2C9 *3 and CYP2C9*13)in the metabolism of lornoxicam in humans[J]. Drug Metab Dispos, 2005;33:749-753.
[19] DeLozier TC, Lee SC, Coulter SJ, et al. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians[J]. J Pharmacol Exp Ther, 2005;315:1085-1090.
[20] 陈马昆, 王睿, 王静.固相萃取HPLC 检测生物样品中甲苯磺丁脲和代谢产物及其人体药代动力学研究[J]. 药物分析, 2005;25:50-54.
[21] Scott J, Poffenbarger PL.Pharmacogenetics of tolbutamide metabolism in humans[J]. Diabetes, 1979;28:41-51.
[22] Veronese ME, Mackenzie PI, Doecke CJ.Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9[J]. Biochem biophys res Commun, 1991;175:1112-1118.
[23] Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polyhymorphism[J]. Pharmacogenetics, 1996;6:341-349.
[24] Lee CR, Pieper JA, Hinderliter AL.Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes[J]. Clin Pharmacol Ther, 2002;72:562-571.
[25] Kirchheiner J, Bauer S, Meineke, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers[J]. Pharma- cogenetics, 2002;12:101-109.
[26] Shon JH, Yoon YR, Kim KA, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans[J]. Pharmacogenetics, 2002;12:111-119.
[27] Jetter A, Kinzig-SchippersM, Skott A, et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide[J]. Eur J Clin Pharmacol, 2004;60:165-171.
[28] Rydberg T, Jonsson A, Roder M.Hypoglycemic activity of glyburide (glibenclamide)metabolites in humans[J]. Diabetes Care, 1994;17:1026-1030.
[29] Dahl-Puustinen ML, Alm C, Bertilsson L, et al. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes[J]. Br J Clin Pharmacol,1990;30:476-480.
[30] Yin OQ, Tomlinson B, Chow MS.CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects[J]. Clin Pharmacol Ther, 2005;78:370-377.
[31] Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002;72:326-332.
[32] 张逸凡, 陈笑艳, 郭颖杰, 等.细胞色素P450 CYP2C93 3 对格列本脲和氯诺昔康中国人体药代动力学的影响[J]. 药学学报, 2005;40:796-799.
[33] Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers[J]. Clin Pharmacol Ther, 2002;71:286-296.
[34] Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypogly cemia in medication with sulfonylurea antidiabetics[J]. Br J Clin Pharmacol, 2005;60:103-106.
[35] Niemi M, Backman JT, Neuvonen M.Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide[J]. Clin Pharmacol Ther, 2001;69:400-406.
[36] Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of chlorpheniramine phenytoin glipizide and nifedipine in individual homozygous for the CYP2C9 *3 allele[J]. Pharmacogenetics,1999;9:71-80.
[37] Campbell RK.Glimepiride:Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[J]. Ann Pharmacother,1998;32:1044-1052.
[38] Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002;72:326-332.
[39] Wang R, Chen K, Wen SY, et al. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms[J]. Clin Pharmacol Ther, 2005;78:90-92.
[40] Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes[J]. Diabetes Res Clin Pract, 2006;72:148-154.